Ischemic Stroke
Conditions
Brief summary
The objective of this study was to evaluate the safety and efficacy of early submaximal balloon angioplasty combined with medical therapy vs medical therapy alone for minor stroke/transient ischemic attack with intracranial atherosclerosis etiology.
Detailed description
In this study, 416 patients with minor strokes or transient ischemic attacks due to symptomatic intracranial atherosclerotic stenosis within one week of the onset of last ischemic symptoms from 20 centers in China were enrolled. The observation group received early submaximal balloon angioplasty, while the control group received only medical therapy. Two groups will be followed up for 1 year to evaluate the safety and efficacy of early submaximal balloon angioplasty combined with medical therapy vs medical therapy alone for minor stroke / transient ischemic attack with intracranial atherosclerosis etiology.
Interventions
PROCEDURESubmaximal balloon angioplasty
The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
Sponsors
The General Hospital of Northern Theater Command
Shouchun Wang, MD, PhD
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Inclusion criteria
1. age range of 30-80 years; 2. symptomatic ICAS (C4-C7 segments of ICA, M1 segment of the MCA, V4 segment of the VA, and BA) with 70%-99% stenosis confirmed by DSA; 3. minor stroke (NIHSS score ≤5) within 1 week of onset or from symptom exacerbation (NIHSS score increased by ≥2 points) or intermediate- to high-risk TIA, defined as ABCD2 score ≥4 within 1 week of the last symptom episode; 4. diameter of the culprit artery ranging from 2.0 to 4.5mm, and the length of the stenosis≤14mm; 5. mRS ≤ 2 before endovascular treatment； 6. no large ischemic region found on CT or MRI (ASPECTS≥ 6 or pc-ASPECTS ≥8)； 7. written informed consent obtained from the patient or legally responsible person.
Exclusion criteria
1. allergy to contrast media; 2. non-atherosclerotic disease-related stenosis, such as arterial dissection, Moya-Moya disease, and arteritis; 3. penetrating branch lesion ipsilateral to the target lesion (infarction caused by penetrating branch occlusion is defined as stenosis of the MCA or BA, but only with simple basal ganglia or brainstem/thalamic infarction); 4. presence of severe stenosis of the extracranial segment on the side of the target lesion; 5. previous endovascular treatment of the ipsilateral vessel; 6. presence of intracranial aneurysms, tumors, and vascular malformations; 7. any form of ipsilateral intracranial hemorrhage within 3 months and contralateral intracranial hemorrhage within 2 weeks; 8. presence of atrial fibrillation, severe heart dysfunction, liver or kidney dysfunction; patients with tumors and serious diseases whose expected survival time is ≤ 1 year; 9. hemoglobin ≤ 100g/L, platelet count ≤ 100×10\^9/L, INR\> 1.5 (irreversible), coagulopathy or irremediable bleeding factors; 10. uncontrollable hypertension: systolic blood pressure \>185 mmHg and/or diastolic blood pressure \>110 mmHg; 11. poor glycemic control (random blood glucose \> 22.2 mmol/L); 12. history of major surgery within 30 days prior to enrollment or surgery plan within 90 days after enrollment; 13. pregnancy or lactation; 14. other conditions that the researchers think make the patient unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stroke or death within 30 days or ischemic stroke in the culprit artery territory from 30 days to 1 year | 30 days, 1 year | Stroke or death within 30 days or ischemic stroke in the culprit artery territory from 30 days to 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stroke or death within 30 days after enrollment | 30 days | Stroke or death within 30 days after enrollment |
| Ischemic stroke in the territory of criminal artery from 30 days to 1 year after enrollment | 1 year | Ischemic stroke in the territory of criminal artery from 30 days to 1 year after enrollment |
| Restenosis rate of criminal artery within 1 year after enrollment | 1 year | Restenosis rate of criminal artery within 1 year after enrollment |
| Evaluation of neurological function improvement within 90 days of enrollment | 90 days | Evaluation of neurological function improvement within 90 days of enrollment |
Other
| Measure | Time frame | Description |
|---|---|---|
| Intracranial hemorrhage within 30 days of enrollment | 30 days | Intracranial hemorrhage within 30 days of enrollment |
| Complications associated with endovascular therapy | 24 hours, discharge, 30 days, 90 days, and 1 year after enrollment | Complications associated with endovascular therapy |
Countries
China
Contacts
Primary ContactShouchun Wang, MD, PhD
Backup ContactHuisheng Chen, MD, PhD
Outcome results
None listed